Meeting of the Working Group on Finance and Taxation at BioEquity in Amsterdam
In the run-up to BioEquity in Amsterdam, the EBD Group invited members to the thirteenth meeting of the Working Group on Finance and Taxation. The following topics were discussed:
From Project Evaluation to Portfolio Management – Best Practices and Pitfalls: Iver Twelsiek, CFA PWC – Valuation and Strategy – LS Team.
Venture Capital Perspectives on the Biotechnology Industry from the Benelux: Christina Takke, Ph.D., Principal, Forbion Capital Partners.
Capital Markets and Biotechnology in the Benelux: Maurice Laudy, CFCM Head Life Sciences; Gerald Verweij, Head of Equity Capital Markets, Amsterdam; Christoph Osterbrink, CFCM, Frankfurt Fortis Merchant Banking.
Deficit Carried Forward – Approaches to and Discussion on a Constitutional Complaint: Wolfgang Weitnauer, Weitnauer Attorneys.
State-of-Play in the Legislative Procedure on the Law on the Modernisation of Conditions for Capital Investments (MoRaKG) and on the Limitation of Risks in Financial Investment and the Report by the Expert Commission for Research and Innovation: Antje Liebers, KPMG; Dirk Honold, BRAIN AG.
In order to make the group’s work more efficient and to deal with several topics at the same time, specific working groups that will prepare certain subjects between the meetings and develop their content were set up. The working group decided to focus on the following areas:
- Tax Issues Resulting from Deficit Carried Forward – Dealing with the Current Legislation
- Tax Incentives in Research Promotion – Suggestions for Amendments to the Legislation
- Law on the Modernisation of Accounting – Effects on Biotech Companies
- Capital Market Issues